SAN DIEGO--(BUSINESS WIRE)--
Retrophin, Inc. (NASDAQ:RTRX), a biopharmaceutical company focused on
the discovery and development of drugs for the treatment of catastrophic
diseases that are debilitating and often life-threatening, and for which
there are currently limited patient options, today announced that it is
offering to sell 5,100,000 shares of its common stock in an underwritten
public offering. In connection with this offering, Retrophin expects to
grant the underwriters a 30-day option to purchase up to an aggregate of
765,000 additional shares of common stock. All of the shares are being
offered by Retrophin. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed or as to the actual size or terms of the
offering. Retrophin anticipates using the net proceeds from the offering
to fund its research and development efforts, acquisitions or
investments in additional complementary businesses, products and
technologies, and for general corporate purposes, including working
capital.
Leerink Partners and Deutsche Bank Securities are acting as joint
book-running managers for the offering.
The securities described above are being offered by Retrophin pursuant
to a shelf registration statement previously filed with and declared
effective by the Securities and Exchange Commission (the "SEC") on March
13, 2015. A preliminary prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC and are
available for free on the SEC's website at http://www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus relating to these securities may also be obtained from
Leerink Partners LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA, 02110, or by email at syndicate@leerink.com,
or by phone at (800) 808-7525, or from Deutsche Bank Securities Inc.,
Attn: Prospectus Department, 60 Wall Street, New York, New York
10005-2836, or at 1-800-503-4611 or prospectus.cpdg@db.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
Forward-Looking Statements
In addition to historical facts, this press release contains
forward-looking statements that involve a number of risks and
uncertainties such as those, among others, relating to Retrophin's
expectations regarding the completion, timing and size of its proposed
public offering. Among the factors that could cause actual results to
differ materially from those indicated in the forward-looking statements
are risks and uncertainties associated with market conditions and the
satisfaction of customary closing conditions related to the proposed
offering, as well as risks and uncertainties associated with Retrophin's
business and finances in general, and the other risks described in
Retrophin's annual report on Form 10-K and Form 10-K/A for the year
ended December 31, 2014 and other filings with the SEC. Retrophin
undertakes no obligation to update the statements contained in this
press release after the date hereof.
Retrophin, Inc.
Chris Cline, CFA, 646-564-3680
Manager,
Investor Relations
IR@retrophin.com
Source: Retrophin, Inc.
News Provided by Acquire Media